Raymond James Financial Inc. upgraded Davita Inc (NYSE:DVA) to Outperform in a report released today.
- Updated: September 20, 2016
Raymond James Financial Inc. has upgraded Davita Inc(NYSE:DVA) to Outperform in a statement released on 9/20/2016.
Just yesterday Davita Inc (NYSE:DVA) traded 0.00% even at $65.22. DVA’s 50-day average is $67.46 and its 200-day average is $73.22. With the last close down 13.14% from the two hundred day average, compared to the Standard & Poor’s 500 Index which has fallen -0.01% over the same time period. Trade volume was down over the average, with 3,747 shares of DVA changing hands under the typical 1,506,600 shares..
Davita Inc has a 52 week low of $61.36 and a 52 week high of $78.94 with a P/E ratio of 37 and has a total market value of $0.0.
In addition to Raymond James Financial Inc. reporting its stock price target, a total of 9 brokers have issued a report on Davita Inc. The consensus target price is $77.00 with four firms rating the stock a strong buy, one analyst rating the stock a buy, seven analyts rating the stock a hold, one analyst rating the stock to underperform, and lastly 0 brokeragesrating the company as sell.
General Company Details For Davita Inc (NYSE:DVA)
DaVita Inc., formerly DaVita HealthCare Partners Inc., is a provider of kidney care services. The Company operates Kidney Care division and HealthCare Partners (HCP) division. The Company’s segments include U.S. dialysis and related lab services, HCP and Other-Ancillary services and strategic initiatives. The Company’s Kidney Care division is a provider of dialysis services in the United States, and treating patients with chronic kidney failure and end stage renal disease (ESRD). HCP division is a patient and physician-focused integrated health care delivery and management company.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.